Optimizing treatment in recurrent epithelial ovarian cancer.

Related Articles Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017 Dec;17(12):1147-1158 Authors: Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G Abstract INTRODUCTION: Optimal management of recurrent ovarian cancer (ROC) remains an area of uncertainty. An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease and median survival for these patients’ ranges from 12 months to 24 months. Many patients receive several lines of treatment following recurrence and, although each subsequent line of therapy is characterized by shorter disease-free intervals, decisions about the most…
Origen: Optimizing treatment in recurrent epithelial ovarian cancer. – PubMed